Today's Clinical Lab - News, Editorial and Products for the Clinical Laboratory
The word Lupus is surrounded by pills and medical supplies on a blue background.
Lupus nephritis is one of the most frequent and severe clinical manifestations of systemic lupus erythematosus, and the leading cause of death.

Improved, Robust Biomarkers for Lupus Nephritis Discovered

Antibodies and DNA amplification techniques were used to detect ultra-low levels of active renal lupus biomarkers

University of Houston
Published:Jan 22, 2024
|2 min read
Register for free to listen to this article
Listen with Speechify

New biomarkers with improved diagnostic performance for early detection of lupus nephritis have been discovered in the University of Houston’s Mohan Lab, led by Chandra Mohan, MD, PhD, a pioneer in lupus research. Early identification of renal involvement in lupus and prompt treatment are essential in reducing the pain, suffering, and eventual mortality it causes. 

What happens in lupus?

Systemic lupus erythematosus (SLE), commonly called lupus, is an autoimmune disease that occurs when the body attacks its tissues and organs. Inflammation from the disease can impact many different parts of the body, including joints, skin, kidneys, blood cells, brain, and heart. Lupus nephritis, affecting the kidneys, is one of the most frequent and severe clinical manifestations of SLE, and the leading cause of death. 

As reported by Mohan, the Hugh Roy and Lillie Cranz Cullen endowed professor of biomedical engineering, in the Journal of Autoimmunity, “These studies add at least six novel urine biomarkers of active renal lupus validated across two ethnically diverse patient cohorts.” 

“We, and others, have reported several urine proteins that can serve as harbingers of renal involvement in lupus. Here, we report on a novel technique based on the use of antibodies and DNA amplification that can detect even low concentrations of proteins. This technique is called proximity extension assay (PEA),” said Mohan. 

Detecting lupus using PEA

By applying PEA proteomics to urine samples, Mohan and the team identified several proteins that were significantly elevated in the urine of lupus patients with active renal disease.  

The study offered independent validation of several previously reported urine biomarkers for active renal lupus, including proteins such as ALCAM, CD163, MCP1, SELL, ICAM1, VCAM1, NGAL, and TWEAK. The researchers also identified additional urine protein biomarkers not previously reported, including ICAM-2, FABP4, FASLG, IGFBP-2, SELE, and TNFSF13B/BAFF.  

Examining the renal expression of these molecules suggests that both immune cells and non-immune cells in the kidneys may be releasing these biomarker proteins into the urine. "These studies have expanded the repertoire of urinary proteins that can be used to monitor renal status in a patient with lupus,” said Mohan.